查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1868949

外泌体诊断和治疗市场：按产品、技术、来源、应用和最终用户划分 - 全球预测（2025-2032 年）

Exosome Diagnostics & Therapeutics Market by Product, Technology, Source, Application, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 188 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，外泌体诊断和治疗市场将成长至 46.9 亿美元，复合年增长率为 18.80%。

关键市场统计数据
基准年 2024 11.8亿美元
预计年份：2025年 13.9亿美元
预测年份 2032 46.9亿美元
复合年增长率 (%) 18.80%

这是一份权威的入门指南，说明了外泌体为何正在重塑诊断和治疗，并为相关人员明确了操作和转化方面的优先事项。

随着科学进步、技术创新和临床检验的融合，外泌体在诊断和治疗领域的应用正迅速发展，其转化潜力也得以充分释放。作为核酸、蛋白质和脂质的天然奈米级载体，外泌体具有两大应用前景：首先，可作为微创生物标记物，用于改进疾病的检测和监测；其次，可作为新型标靶治疗药物递送载体。近年来，分子生物学、生物工程和临床医学等领域的跨学科合作不断加强，推动了外泌体分离方法、表征平台和应用特异性检测技术的突破性进展。

重点检验相互依存的技术、临床和商业性转折点，这些转折点将推动外泌体研发和市场策略发生根本性转变。

过去十年，外泌体科学在技术、临床和商业性方面都发生了变革性变化，重塑了相关人员进行诊断和治疗方法研发的方式。在技​​术方面，微流体、亲和性和捕获和新一代分析技术的创新提高了外泌体分离和分子谱分析的灵敏度和特异性，使得从复杂的生物体液中检测具有临床意义的讯号成为可能。在临床方面，来自观察性研究和早期干预的不断累积的数据正在明确外泌体衍生生物标记的应用场景，这些场景可以补充甚至超越现有方法，尤其是在肿瘤学和神经退化性疾病的监测方面。

对 2025 年关税重组如何重塑外泌体价值链的供应链韧性、筹资策略和专案时间表进行详细评估。

2025年，美国关税政策的变化正透过成本、供应链和策略采购等诸多因素的复杂交织，对全球外泌体生态系统产生影响。关税调整提高了某些用于外泌体分离和表征的进口材料和设备的相对成本，促使各机构重新评估筹资策略和供应商集中风险。对于特殊试剂、精密仪器和组件而言，这种变化尤其显着，因为这些製造地主要集中在受关税影响的贸易路线之外。

将产品、技术、来源、临床应用和最终用户趋势与策略发展和商业化选择联繫起来的综合細項分析

细分市场为理解产品优先顺序、技术权衡、生物原材料、临床适应症和最终用户需求提供了一个实用的框架，这些因素共同塑造了投资和开发策略。依产品、仪器、试剂盒和软体服务进行分析，可以发现它们各自独特的商业化需求。仪器需要资本投资和生命週期服务模式，而试剂盒则需要批次间一致性和监管控制。同时，软体和服务（包括咨询服务和数据分析）依赖可重复的演算法、检验的流程和可扩展的资料管治结构。由于每种产品类型与监管要求的交互方式各不相同，产品负责人必须使检验策略与预期用途保持一致，同时设计能够反映诊断实验室、学术机构和产业伙伴采购行为的商业模式。

提供切实可行的区域信息，阐述美洲、欧洲、中东和非洲以及亚太地区的趋势将如何影响临床检验、生产和市场进入策略。

区域趋势对外泌体诊断和治疗领域的研究、临床检验、生产和市场进入等策略重点有显着影响。在美洲，活跃的研究和生物技术投资正在推动转化研究的快速发展，建立了一个强大的风险投资、学术和临床试验生态系统，为早期创新和试点临床试验提供支援。该地区的法规结构和支付方互动也在塑造证据标准，鼓励各机构设计能够证明临床效用并指南报销策略的实用性临床试验。

对竞争定位和合作模式的策略评估揭示了整合平台和检验的服务产品为何正在成为市场差异化因素。

外泌体诊断和治疗领域的竞争动态凸显了一个多元化的生态系统，其中仪器製造商、试剂开发商、平台开发商和服务供应商在相邻的价值链环节竞争。领先的技术开发人员正致力于透过提高分离特异性、整合工作流程以及检验的分析技术来提升效能差异化，从而降低变异性并加快结果获取速度。与仪器和试剂的创新同步，软体和服务供应商的重要性日益凸显，他们提供的咨询服务和数据分析框架能够将原始分子讯号转化为具有临床意义的见解。随着客户寻求能够与实验室营运和临床决策流程整合的端到端解决方案，而不仅仅是硬体和耗材，这些能力正成为关键的差异化因素。

为加速临床应用和商业性永续性，提供整合技术选择、监管准备、供应链韧性和证据产生的实用建议

致力于将科学进步转化为永续商业性成果的行业领导者应优先考虑整合检测性能、生产准备、法规遵从性和支付方参与等各个环节的整合策略。首先，企业必须采用适用的平台方法，使技术选择与预期临床用途相匹配，确保分离和表征方法符合所选适应症的敏感度和特异性要求。其次，建立健全的品管系统并与监管机构儘早沟通，将最大限度地减少后期阶段的意外情况，并有助于顺利推进临床和商业化进程。第三，建立包含检验的分析方法、透明演算法和可互通报告格式的数据策略，将增强临床信心，并促进与电子健康记录 (EHR) 和实验室资讯系统 (LIS) 的整合。

说明多模态调查方法，将与关键相关人员的直接对话和技术基准化分析相结合，以得出检验且可操作的研究结果。

本研究采用多模态调查方法，结合与关键相关利益者的直接对话、二手文献综合分析以及严格的交叉检验，以确保对外泌体诊断和治疗领域有全面而务实的理解。主要研究内容包括对科学领导者、临床研究人员、采购专业人员和产业高管进行结构化访谈，以收集关于技术能力、营运限制和策略重点的第一线观点。这些定性见解与同行评审文章、监管指导文件和技术白皮书进行三角验证，从而为科学论点和运营挑战提供背景资讯。

简要概述重点阐述了检验、生产和伙伴关係的整合执行将如何决定哪些外泌体创新能够取得临床和商业性的成功。

总之，外泌体诊断和治疗领域正处于一个转折点，科学可行性与检验、生产和市场接受等实际需求交汇融合。分离技术的进步、分子分析的先进性以及临床需求的不断增长，为新型诊断和治疗方法的开发创造了沃土。然而，将这种潜力转化为实际应用，需要平台选择与临床需求精准匹配，加大对品质和规模的投入，并对供应炼和监管方面的复杂性进行策略性管理。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 制定标准化的分离和表征通讯协定，以确保临床外泌体应用中的可重复性
  • 基于外泌体的液态生物检体检测在多种癌症早期检测中的进展
  • 生技公司与学术机构的策略合作加速了外泌体疗法研发进程。
  • 合成外泌体模拟物的出现，旨在实现靶向药物递送并提高体内稳定性
  • 整合人工智慧和机器学习以增强外泌体生物标记发现和分析工作流程
  • 引入临床级外泌体生产的新监管指南和品质标准

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 外泌体诊断与治疗市场（依产品划分）

  • 装置
  • 试剂和试剂盒
  • 软体和服务
    • 咨询服务
    • 数据分析

第九章 外泌体诊断与治疗市场（依技术划分）

  • 滤
  • 亲和性和捕获
  • 微流体技术
  • 聚合物沉淀
  • 超速离心

第十章 外泌体诊断与治疗市场（依来源划分）

  • 母乳
  • 脑脊髓液
  • 唾液
  • 血清/血浆
  • 尿

第十一章 外泌体诊断与治疗市场（依应用领域划分）

  • 癌症
    • 乳癌
    • 大肠直肠癌
    • 肺癌
    • 摄护腺癌
  • 心血管疾病
  • 感染疾病
  • 神经退化性疾病
  • 产前检查
  • 治疗应用
    • 药物输送
    • 基因治疗

第十二章 外泌体诊断与治疗市场（依最终使用者划分）

  • 学术机构
  • 诊断实验室
  • 医院
  • 製药和生物技术公司
  • 研究所，
  • 专科诊所

第十三章 外泌体诊断与治疗市场（按地区划分）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章 外泌体诊断与治疗市场（依组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 各国外泌体诊断与治疗市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • AEGLE Therapeutics
    • Aethlon Medical Inc.
    • AMS Biotechnology
    • Bio-Techne Corporation
    • Capital Biosciences, Inc.
    • Capricor Therapeutics, Inc.
    • Celularity Inc.
    • Direct Biologics LLC
    • Evox Therapeutics Limited
    • ExoCoBio Inc.
    • EXOGENUS THERAPEUTICS, SA
    • Exosome biotech company
    • ILIAS Biologics Inc.
    • KIMERA LABS
    • Lonza Group AG
    • Mercy Bioanalytics
    • NanoFCM Co., Ltd
    • NanoSomiX, Inc.
    • NeuroSense Therapeutics Ltd.
    • Promega Corporation
    • PureTech Health plc
    • ReNeuron Group plc
    • RION
    • Sienna Cancer Diagnostics Ltd
    • System Biosciences, LLC
Product Code: MRR-4F7B2F382F30

The Exosome Diagnostics & Therapeutics Market is projected to grow by USD 4.69 billion at a CAGR of 18.80% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 1.18 billion
Estimated Year [2025] USD 1.39 billion
Forecast Year [2032] USD 4.69 billion
CAGR (%) 18.80%

An authoritative primer explaining why exosomes are reshaping diagnostics and therapeutics while defining the operational and translational priorities for stakeholders

The exosome diagnostics and therapeutics landscape is evolving rapidly as scientific advances, technological innovation, and clinical validation converge to unlock the translational potential of extracellular vesicles. Exosomes, as naturally occurring nano-scale carriers of nucleic acids, proteins, and lipids, present dual opportunities: they serve as minimally invasive biomarkers that improve disease detection and monitoring, and they offer novel vectors for targeted therapeutic delivery. Over the past several years, multidisciplinary efforts spanning molecular biology, bioengineering, and clinical medicine have intensified, driving breakthroughs in isolation methods, characterization platforms, and application-specific assays.

As regulatory frameworks, stakeholder expectations, and payer perspectives mature, organizations across academia, diagnostics, and pharma are re-evaluating development pathways and commercialization strategies. This introduction highlights the scientific rationale for continued investment, underscores the operational and translational constraints that remain, and frames the strategic implications for executives and R&D leaders. Consequently, the industry now faces a pivotal phase in which robust analytical validation, scalable manufacturing, and alignment with clinical utility are prerequisites for broader adoption. By clarifying the key levers that influence both diagnostic and therapeutic trajectories, leaders can prioritize resource allocation to accelerate credible productization and meaningful clinical uptake.

A focused examination of interdependent technical, clinical, and commercial inflection points driving a fundamental reorientation of exosome R&D and market approaches

The past decade has delivered transformative shifts across technical, clinical, and commercial dimensions of exosome science, reshaping how stakeholders approach both diagnostics and therapeutic development. Technically, innovations in microfluidics, immune affinity capture, and next-generation analytics have improved the sensitivity and specificity of exosome isolation and molecular profiling, enabling the detection of clinically relevant signals from challenging biofluids. Clinically, the aggregation of observational studies and early interventional data has begun to delineate contexts of use where exosome-derived biomarkers can complement or outperform existing modalities, especially in oncology and neurodegenerative disease monitoring.

Commercially, parallel developments in data analytics and service models have enabled new go-to-market strategies that emphasize platform monetization, clinical partnerships, and value-based evidence generation. Moreover, the maturation of regulatory dialogue around companion diagnostics and biologic delivery systems has prompted firms to adopt more rigorous quality systems and engage earlier with health authorities. These shifts are not isolated; they interact, compelling companies to integrate engineering robustness with clinical validation and reimbursement planning. Consequently, organizations that can synthesize cross-functional expertise-combining assay development, scalable manufacturing, and health-economics modeling-will capture first-mover advantages and reduce time-to-clinic for both diagnostic assays and exosome-based therapeutics.

A nuanced assessment of how tariff reconfigurations in 2025 have reshaped supply chain resilience, sourcing strategies, and program timelines across the exosome value chain

In 2025, changes to United States tariff policy have created a complex overlay of cost, supply chain, and strategic sourcing considerations that influence the global exosome ecosystem. Tariff adjustments increased the relative cost of certain imported materials and instruments widely used in exosome isolation and characterization, which in turn has incentivized organizations to reassess procurement strategies and supplier concentration risk. This shift has been particularly salient for specialized reagents, precision instrumentation, and components that have limited manufacturing footprints outside tariff-affected trade corridors.

As a consequence, procurement teams and development leaders are responding by diversifying supplier bases, increasing inventory buffers for critical consumables, and accelerating qualification of domestic or tariff-exempt suppliers. Moreover, the tariff landscape has catalyzed longer-term conversations about nearshoring and regional manufacturing partnerships to reduce exposure to policy volatility. Importantly, these reactions extend beyond cost substitution: they influence product development timelines because new supplier qualifications require additional analytical verification and documentation. Therefore, executive teams must integrate tariff-driven supply chain resilience into program planning, ensuring that sourcing decisions align with regulatory submission schedules and clinical deployment timelines. In short, tariffs have become a structural factor that shapes operational resilience, strategic partnerships, and the economics of scaling both diagnostic platforms and therapeutic manufacturing.

Comprehensive segmentation insights that connect product, technology, source, clinical application, and end-user dynamics to strategic development and commercialization choices

Segmentation provides a practical framework for understanding product priorities, technological trade-offs, biological sources, clinical indications, and end-user requirements that collectively shape investment and development strategies. When analyzed by product, instruments, reagents and kits, and software and services reveal distinct commercialization imperatives: instruments demand capital investment and lifecycle service models, reagents and kits require robust lot-to-lot consistency and regulatory control, while software and services, which further encompass consulting services and data analysis, hinge on reproducible algorithms, validated pipelines, and scalable data governance structures. Each product category interacts with regulatory expectations differently, so product leaders must align validation strategies to intended use while designing commercial models that reflect procurement behaviors in diagnostic laboratories, academic centers, and industry partners.

Examining the market by technology emphasizes how the choice of platform-whether filtration, immune affinity capture, microfluidics, polymer precipitation, or ultracentrifugation-affects analytical performance, throughput, and compatibility with downstream assays. Filtration and microfluidic approaches prioritize throughput and integration with automated workflows, immune affinity capture offers biomarker-selective enrichment that can enhance signal-to-noise for specific applications, polymer precipitation provides a cost-effective route for bulk isolation but may require additional purification steps for high-precision assays, and ultracentrifugation remains a research-standard method that presents scale and reproducibility constraints for routine clinical use. Understanding these trade-offs enables R&D teams to make technology choices consistent with their clinical and commercial objectives.

Source-based segmentation across breast milk, cerebrospinal fluid, saliva, serum and plasma, and urine defines both the biological opportunities and the pre-analytical challenges associated with exosome-based products. Biofluid selection determines assay sensitivity requirements, sample collection protocols, and regulatory pathways because each matrix presents unique matrix effects and stability considerations. For instance, serum and plasma are established clinical sample types that facilitate adoption but require stringent hemolysis control, whereas cerebrospinal fluid can provide higher disease-specific signal at the cost of invasive collection procedures. Similarly, saliva, urine, and breast milk open avenues for noninvasive testing and pediatric applications, yet they demand tailored extraction and normalization strategies.

Application-driven segmentation into cancer, cardiovascular diseases, infectious diseases, neurodegenerative diseases, prenatal diagnosis, and therapeutic applications illuminates where clinical need intersects with technical feasibility. Within oncology, disease-specific focuses such as breast cancer, colorectal cancer, lung cancer, and prostate cancer each require unique biomarker panels and validation cohorts. Therapeutic applications, including drug delivery and gene therapy, necessitate stringent control over exosome characterization, payload loading, and safety profiling. Across indications, demonstrating clinical utility-evidence that the test or therapeutic changes patient management and outcomes-remains the central gating factor for adoption and reimbursement.

Finally, end-user segmentation-spanning academic institutes, diagnostic laboratories, hospitals, pharmaceutical and biotechnology companies, research laboratories, and specialized clinics-highlights divergent purchasing behaviors and operational constraints. Academic and research centers often prioritize flexibility and open platforms for exploratory work, whereas diagnostic laboratories and hospitals require validated, robust workflows compatible with existing laboratory information systems and quality management systems. Pharmaceutical and biotechnology companies focus on scalable, GMP-aligned solutions for therapeutic development and clinical trials, and specialized clinics may seek point-of-care compatible tools that support rapid decision-making. Consequently, go-to-market strategies must be tailored to each end-user type, aligning product design, regulatory strategy, and commercial engagement to the operational realities of the intended customer base.

Actionable regional intelligence describing how Americas, Europe Middle East & Africa, and Asia-Pacific dynamics influence clinical validation, manufacturing, and market access strategies

Regional dynamics materially influence strategic priorities for research, clinical validation, manufacturing, and market access in exosome diagnostics and therapeutics. In the Americas, research intensity and biotech investment have driven rapid translational pipelines, with robust venture, academic, and clinical trial ecosystems that support early-stage innovation and pilot clinical implementations. This region's regulatory frameworks and payer dialogues also shape evidentiary standards, prompting organizations to design pragmatic clinical studies that demonstrate clinical utility and inform reimbursement strategies.

Europe, Middle East & Africa present a heterogeneous environment in which regulatory harmonization across jurisdictions sits alongside pockets of specialized clinical expertise and public-private collaboration. Regulatory expectations in several European markets emphasize analytical rigor and real-world evidence generation, while certain Middle Eastern countries are investing in biotechnology infrastructure to attract specialized manufacturing projects. Africa presents both unique unmet needs and logistical challenges, underscoring the importance of adaptable sample collection protocols and context-specific deployment models.

Asia-Pacific is characterized by rapid capacity growth, diversified manufacturing capability, and a large population base that supports expansive clinical validation efforts. Policymakers in several markets are actively supporting biotech industrialization and diagnostics adoption, creating opportunities for commercial scale-up. However, market entry strategies must navigate country-specific regulatory pathways, varying reimbursement models, and differences in clinical practice patterns. Across these regions, companies are increasingly adopting hybrid strategies that combine regional manufacturing, strategic partnerships, and tailored evidence generation plans to address local clinical and commercial requirements.

A strategic assessment of competitive positioning and partnership models revealing why integrated platforms and validated service offerings are emerging as market differentiators

Competitive dynamics in exosome diagnostics and therapeutics reveal a diversified ecosystem of instrument manufacturers, reagent innovators, platform developers, and service providers competing across adjacent value chain segments. Leading technology developers focus on performance differentiation through enhanced isolation specificity, integrated workflows, and validated analytics that reduce variability and accelerate time-to-result. Parallel to instrument and reagent innovation, software and services providers are increasingly essential, offering consulting services and data analysis frameworks that translate raw molecular signals into clinically actionable insights. These capabilities are becoming critical differentiation points as customers demand not only hardware and consumables but also end-to-end solutions that integrate with laboratory operations and clinical decision pathways.

Strategic collaborations and cross-sector partnerships define many recent moves to scale. Diagnostic labs and hospitals are entering co-development agreements with platform providers to ensure clinical applicability, while pharmaceutical and biotech companies are partnering with exosome specialists to develop therapeutic payload delivery systems and to leverage exosome-based biomarkers in clinical trials. Investment in quality systems, regulatory expertise, and scalable manufacturing is a recurring theme, as early victories in analytical performance must be sustained by consistent production and documentation practices suitable for clinical deployment. Thus, competitive positioning increasingly favors organizations that combine technological excellence with operational maturity and a demonstrated ability to generate clinically relevant evidence.

Practical recommendations that align technology selection, regulatory readiness, supply chain resilience, and evidence generation to accelerate clinical adoption and commercial sustainability

Industry leaders seeking to translate scientific advances into sustainable commercial outcomes should prioritize an integrated strategy that bridges assay performance, manufacturing readiness, regulatory navigation, and payer alignment. First, companies must adopt a fit-for-purpose platform approach that aligns technology selection with intended clinical use, ensuring that isolation and characterization methods meet the sensitivity and specificity requirements of the chosen indication. Second, establishing robust quality management systems and early engagement with regulatory authorities will minimize later-stage surprises and support smoother clinical and commercialization pathways. Third, developing data strategies that encompass validated analytics, transparent algorithms, and interoperable reporting formats will enhance clinical trust and facilitate integration with electronic health records and laboratory information systems.

Furthermore, stakeholders should design supply chain strategies that reduce single-source dependencies and incorporate regional manufacturing or qualified alternative suppliers to buffer against policy-driven disruptions. Strategic partnerships with clinical networks and contract research organizations can accelerate evidence generation while enabling broader access to diverse patient cohorts. Lastly, leaders should embed health-economic modeling and real-world evidence frameworks early in program design to demonstrate value to payers and providers. By executing on these priorities in an integrated manner, organizations can increase the likelihood of clinical adoption, reimbursement, and sustainable commercial growth.

A clear description of the multi-modal research methodology combining primary stakeholder engagement and technical benchmarking to produce validated, actionable insights

This research synthesizes a multi-modal methodology combining primary stakeholder engagement, secondary literature synthesis, and rigorous cross-validation to ensure a balanced and actionable understanding of the exosome diagnostics and therapeutics landscape. Primary inputs include structured interviews with scientific leaders, clinical investigators, procurement specialists, and industry executives to capture first-hand perspectives on technology performance, operational constraints, and strategic priorities. These qualitative insights were triangulated with peer-reviewed publications, regulatory guidance documents, and technical white papers to contextualize scientific claims and operational challenges.

Analytical methods emphasize thematic coding of qualitative interviews, technical benchmarking across platform attributes such as sensitivity, specificity, throughput, and scalability, and scenario-based analysis of supply chain and regulatory contingencies. Where appropriate, methodological rigor incorporated reproducibility checks for reported assay performance claims and assessed the maturity of validation evidence. The approach prioritized transparency, documenting assumptions and evidence sources, and employed iterative review with domain experts to reduce bias. Ultimately, the methodology balances depth of technical assessment with strategic considerations relevant to executives making investment and development decisions.

A concise synthesis highlighting how integrated execution across validation, manufacturing, and partnerships will determine which exosome innovations achieve clinical and commercial success

In conclusion, the exosome diagnostics and therapeutics field stands at an inflection point where scientific feasibility increasingly intersects with practical imperatives for validation, manufacturing, and market acceptance. The convergence of improved isolation technologies, advanced molecular analytics, and expanding clinical interest creates fertile ground for novel diagnostics and therapeutic modalities. However, translating promise into practice requires deliberate alignment of platform selection with clinical need, investments in quality and scale, and strategic management of supply chain and regulatory complexity.

Leaders who prioritize integrated evidence generation, operational resilience, and partnerships that bridge laboratory innovation with clinical workflows will be best positioned to capture emerging opportunities. By focusing on reproducibility, interoperability, and demonstrable clinical utility, stakeholders can accelerate responsible adoption and deliver tangible improvements in patient care. The path forward emphasizes disciplined execution as much as scientific creativity, ensuring that exosome-based solutions realize their potential across diagnostics and therapeutics.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Development of standardized isolation and characterization protocols to ensure reproducibility in clinical exosome applications
  • 5.2. Advancements in exosome-based liquid biopsy assays for early detection of multiple cancer types
  • 5.3. Strategic partnerships between biotech firms and academic institutions to accelerate exosome therapeutic pipelines
  • 5.4. Emergence of synthetic exosome mimetics engineered for targeted drug delivery and enhanced stability in vivo
  • 5.5. Integration of artificial intelligence and machine learning to enhance exosomal biomarker discovery and analysis workflows
  • 5.6. Implementation of emerging regulatory guidelines and quality standards for clinical grade exosome manufacturing

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Exosome Diagnostics & Therapeutics Market, by Product

  • 8.1. Instruments
  • 8.2. Reagents and Kits
  • 8.3. Software and Services
    • 8.3.1. Consulting Services
    • 8.3.2. Data Analysis

9. Exosome Diagnostics & Therapeutics Market, by Technology

  • 9.1. Filtration
  • 9.2. Immune Affinity Capture
  • 9.3. Microfluidics
  • 9.4. Polymer Precipitation
  • 9.5. Ultracentrifugation

10. Exosome Diagnostics & Therapeutics Market, by Source

  • 10.1. Breast Milk
  • 10.2. Cerebrospinal Fluid
  • 10.3. Saliva
  • 10.4. Serum & Plasma
  • 10.5. Urine

11. Exosome Diagnostics & Therapeutics Market, by Application

  • 11.1. Cancer
    • 11.1.1. Breast Cancer
    • 11.1.2. Colorectal Cancer
    • 11.1.3. Lung Cancer
    • 11.1.4. Prostate Cancer
  • 11.2. Cardiovascular Diseases
  • 11.3. Infectious Diseases
  • 11.4. Neurodegenerative Diseases
  • 11.5. Prenatal Diagnosis
  • 11.6. Therapeutic Applications
    • 11.6.1. Drug Delivery
    • 11.6.2. Gene Therapy

12. Exosome Diagnostics & Therapeutics Market, by End User

  • 12.1. Academic Institutes
  • 12.2. Diagnostic Laboratories
  • 12.3. Hospitals
  • 12.4. Pharmaceutical and Biotechnologies Companies
  • 12.5. Research Laboratories,
  • 12.6. Specialized Clinics

13. Exosome Diagnostics & Therapeutics Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Exosome Diagnostics & Therapeutics Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Exosome Diagnostics & Therapeutics Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. AEGLE Therapeutics
    • 16.3.2. Aethlon Medical Inc.
    • 16.3.3. AMS Biotechnology
    • 16.3.4. Bio-Techne Corporation
    • 16.3.5. Capital Biosciences, Inc.
    • 16.3.6. Capricor Therapeutics, Inc.
    • 16.3.7. Celularity Inc.
    • 16.3.8. Direct Biologics LLC
    • 16.3.9. Evox Therapeutics Limited
    • 16.3.10. ExoCoBio Inc.
    • 16.3.11. EXOGENUS THERAPEUTICS, S.A.
    • 16.3.12. Exosome biotech company
    • 16.3.13. ILIAS Biologics Inc.
    • 16.3.14. KIMERA LABS
    • 16.3.15. Lonza Group AG
    • 16.3.16. Mercy Bioanalytics
    • 16.3.17. NanoFCM Co., Ltd
    • 16.3.18. NanoSomiX, Inc.
    • 16.3.19. NeuroSense Therapeutics Ltd.
    • 16.3.20. Promega Corporation
    • 16.3.21. PureTech Health plc
    • 16.3.22. ReNeuron Group plc
    • 16.3.23. RION
    • 16.3.24. Sienna Cancer Diagnostics Ltd
    • 16.3.25. System Biosciences, LLC

LIST OF FIGURES

  • FIGURE 1. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SOURCE, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SOURCE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INSTRUMENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY REAGENTS AND KITS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY REAGENTS AND KITS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY REAGENTS AND KITS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY REAGENTS AND KITS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY REAGENTS AND KITS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY REAGENTS AND KITS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SOFTWARE AND SERVICES, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SOFTWARE AND SERVICES, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SOFTWARE AND SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SOFTWARE AND SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SOFTWARE AND SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SOFTWARE AND SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SOFTWARE AND SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SOFTWARE AND SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY CONSULTING SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY CONSULTING SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY CONSULTING SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY CONSULTING SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY CONSULTING SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY CONSULTING SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DATA ANALYSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DATA ANALYSIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DATA ANALYSIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DATA ANALYSIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DATA ANALYSIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DATA ANALYSIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY FILTRATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY FILTRATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY FILTRATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY FILTRATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY FILTRATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY FILTRATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMMUNE AFFINITY CAPTURE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMMUNE AFFINITY CAPTURE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMMUNE AFFINITY CAPTURE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMMUNE AFFINITY CAPTURE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMMUNE AFFINITY CAPTURE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMMUNE AFFINITY CAPTURE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY MICROFLUIDICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY MICROFLUIDICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY MICROFLUIDICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY MICROFLUIDICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY MICROFLUIDICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY MICROFLUIDICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY POLYMER PRECIPITATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY POLYMER PRECIPITATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY POLYMER PRECIPITATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY POLYMER PRECIPITATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY POLYMER PRECIPITATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY POLYMER PRECIPITATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY ULTRACENTRIFUGATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY ULTRACENTRIFUGATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY ULTRACENTRIFUGATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY ULTRACENTRIFUGATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY ULTRACENTRIFUGATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY ULTRACENTRIFUGATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SOURCE, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY BREAST MILK, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY BREAST MILK, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY BREAST MILK, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY BREAST MILK, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY BREAST MILK, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY BREAST MILK, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY CEREBROSPINAL FLUID, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY CEREBROSPINAL FLUID, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY CEREBROSPINAL FLUID, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY CEREBROSPINAL FLUID, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY CEREBROSPINAL FLUID, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY CEREBROSPINAL FLUID, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SALIVA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SALIVA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SALIVA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SALIVA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SALIVA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SALIVA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SERUM & PLASMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SERUM & PLASMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SERUM & PLASMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SERUM & PLASMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SERUM & PLASMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SERUM & PLASMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY URINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY URINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY URINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY URINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY URINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY URINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY CANCER, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY CANCER, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY BREAST CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY BREAST CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY BREAST CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COLORECTAL CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COLORECTAL CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COLORECTAL CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COLORECTAL CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY LUNG CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY LUNG CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY LUNG CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY LUNG CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY LUNG CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PROSTATE CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PROSTATE CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PROSTATE CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PROSTATE CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY NEURODEGENERATIVE DISEASES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY NEURODEGENERATIVE DISEASES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY NEURODEGENERATIVE DISEASES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY NEURODEGENERATIVE DISEASES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY NEURODEGENERATIVE DISEASES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY NEURODEGENERATIVE DISEASES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRENATAL DIAGNOSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRENATAL DIAGNOSIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRENATAL DIAGNOSIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRENATAL DIAGNOSIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRENATAL DIAGNOSIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRENATAL DIAGNOSIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG DELIVERY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG DELIVERY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG DELIVERY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG DELIVERY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG DELIVERY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG DELIVERY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY GENE THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY GENE THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY GENE THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY GENE THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY GENE THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY ACADEMIC INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY ACADEMIC INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY ACADEMIC INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY ACADEMIC INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY ACADEMIC INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY ACADEMIC INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PHARMACEUTICAL AND BIOTECHNOLOGIES COMPANIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PHARMACEUTICAL AND BIOTECHNOLOGIES COMPANIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PHARMACEUTICAL AND BIOTECHNOLOGIES COMPANIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PHARMACEUTICAL AND BIOTECHNOLOGIES COMPANIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PHARMACEUTICAL AND BIOTECHNOLOGIES COMPANIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PHARMACEUTICAL AND BIOTECHNOLOGIES COMPANIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY RESEARCH LABORATORIES,, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY RESEARCH LABORATORIES,, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY RESEARCH LABORATORIES,, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY RESEARCH LABORATORIES,, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY RESEARCH LABORATORIES,, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY RESEARCH LABORATORIES,, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SPECIALIZED CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SPECIALIZED CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SPECIALIZED CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SPECIALIZED CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SPECIALIZED CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SPECIALIZED CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 221. AMERICAS EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 222. AMERICAS EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 223. AMERICAS EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 224. AMERICAS EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 225. AMERICAS EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SOFTWARE AND SERVICES, 2018-2024 (USD MILLION)
  • TABLE 226. AMERICAS EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SOFTWARE AND SERVICES, 2025-2032 (USD MILLION)
  • TABLE 227. AMERICAS EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 228. AMERICAS EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 229. AMERICAS EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2024 (USD MILLION)
  • TABLE 230. AMERICAS EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SOURCE, 2025-2032 (USD MILLION)
  • TABLE 231. AMERICAS EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 232. AMERICAS EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 233. AMERICAS EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY CANCER, 2018-2024 (USD MILLION)
  • TABLE 234. AMERICAS EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY CANCER, 2025-2032 (USD MILLION)
  • TABLE 235. AMERICAS EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2024 (USD MILLION)
  • TABLE 236. AMERICAS EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2025-2032 (USD MILLION)
  • TABLE 237. AMERICAS EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 238. AMERICAS EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 239. NORTH AMERICA EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 240. NORTH AMERICA EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 241. NORTH AMERICA EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 242. NORTH AMERICA EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 243. NORTH AMERICA EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SOFTWARE AND SERVICES, 2018-2024 (USD MILLION)
  • TABLE 244. NORTH AMERICA EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SOFTWARE AND SERVICES, 2025-2032 (USD MILLION)
  • TABLE 245. NORTH AMERICA EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 246. NORTH AMERICA EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 247. NORTH AMERICA EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2024 (USD MILLION)
  • TABLE 248. NORTH AMERICA EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SOURCE, 2025-2032 (USD MILLION)
  • TABLE 249. NORTH AMERICA EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 250. NORTH AMERICA EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 251. NORTH AMERICA EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY CANCER, 2018-2024 (USD MILLION)
  • TABLE 252. NORTH AMERICA EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY CANCER, 2025-2032 (USD MILLION)
  • TABLE 253. NORTH AMERICA EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2024 (USD MILLION)
  • TABLE 254. NORTH AMERICA EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2025-2032 (USD MILLION)
  • TABLE 255. NORTH AMERICA EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 256. NORTH AMERICA EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 257. LATIN AMERICA EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 258. LATIN AMERICA EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 259. LATIN AMERICA EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 260. LATIN AMERICA EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 261. LATIN AMERICA EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SOFTWARE AND SERVICES, 2018-2024 (USD MILLION)
  • TABLE 262. LATIN AMERICA EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SOFTWARE AND SERVICES, 2025-2032 (USD MILLION)
  • TABLE 263. LATIN AMERICA EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 264. LATIN AMERICA EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 265. LATIN AMERICA EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2024 (USD MILLION)
  • TABLE 266. LATIN AMERICA EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SOURCE, 2025-2032 (USD MILLION)
  • TABLE 267. LATIN AMERICA EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 268. LATIN AMERICA EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 269. LATIN AMERICA EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY CANCER, 2018-2024 (USD MILLION)
  • TABLE 270. LATIN AMERICA EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY CANCER, 2025-2032 (USD MILLION)
  • TABLE 271. LATIN AMERICA EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2024 (USD MILLION)
  • TABLE 272. LATIN AMERICA EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2025-2032 (USD MILLION)
  • TABLE 273. LATIN AMERICA EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 274. LATIN AMERICA EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 275. EUROPE, MIDDLE EAST & AFRICA EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 276. EUROPE, MIDDLE EAST & AFRICA EXOSOME DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 277. EUROPE, MIDDLE EAST & AFRICA EXOSOME DIAGNOSTICS